Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch

Abstract Background The reliability of clinical practice guidelines has been disputed because guideline panel members are often burdened with financial conflicts of interest (COI). Current recommendations for COI regulation advise not only detailed declaration but also active management of conflicts...

Full description

Bibliographic Details
Main Authors: Hendrik Napierala, Luise Schäfer, Gisela Schott, Niklas Schurig, Thomas Lempert
Format: Article
Language:English
Published: BMC 2018-06-01
Series:BMC Medical Ethics
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12910-018-0309-y
id doaj-e17e2c21acb2428291aaa2243325028d
record_format Article
spelling doaj-e17e2c21acb2428291aaa2243325028d2020-11-25T03:56:49ZengBMCBMC Medical Ethics1472-69392018-06-011911710.1186/s12910-018-0309-yManagement of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatchHendrik Napierala0Luise Schäfer1Gisela Schott2Niklas Schurig3Thomas Lempert4Charité UniversitätsmedizinCharité UniversitätsmedizinDrug Commission of the German Medical AssociationFamily PracticeDepartment of Neurology, Schlosspark-KlinikAbstract Background The reliability of clinical practice guidelines has been disputed because guideline panel members are often burdened with financial conflicts of interest (COI). Current recommendations for COI regulation advise not only detailed declaration but also active management of conflicts. To continuously assess COI declaration and management in German guidelines we established the public database LeitlinienWatch (GuidelineWatch). Methods We analyzed all German guidelines at the highest methodological level (S3) that included recommendations for pharmacological therapy (n = 67) according to five criteria: declaration and assessment of COI, composition of the guideline development group, independence of the coordinators and lead authors, imposed abstentions because of COI and public external review. Each criterion was assessed using predefined outcome categories. Results Most guidelines (76%) contained a detailed declaration of COI. However, none of the guidelines provided full transparency of COI assessment results. The guideline group was composed of a majority of participants with COI in 55% of the guidelines, no guideline was free of participants with COI. Only 9% of guidelines had coordinators and lead authors without any financial COI. Most guidelines (70%) did not provide a rule for abstentions for participants with COI. In 21% of guidelines there was a rule, but abstentions were either not practiced or not documented, whereas in 7% partial abstentions and in 2% complete abstentions were documented. Two thirds of the guideline drafts (67%) were not externally reviewed via a public website. Conclusions COI are usually documented in detail in German guidelines of the highest methodological level. However, considerable improvement is needed regarding active management of COI, including recruitment of independent experts for guideline projects, abstention from voting for participants with COI and external review of the guideline draft. We assume that the publicly available ratings on GuidelineWatch will improve the handling of conflicts of interest in guideline development.http://link.springer.com/article/10.1186/s12910-018-0309-yClinical practice guidelinesConflict of interestTransparencyRegulation
collection DOAJ
language English
format Article
sources DOAJ
author Hendrik Napierala
Luise Schäfer
Gisela Schott
Niklas Schurig
Thomas Lempert
spellingShingle Hendrik Napierala
Luise Schäfer
Gisela Schott
Niklas Schurig
Thomas Lempert
Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch
BMC Medical Ethics
Clinical practice guidelines
Conflict of interest
Transparency
Regulation
author_facet Hendrik Napierala
Luise Schäfer
Gisela Schott
Niklas Schurig
Thomas Lempert
author_sort Hendrik Napierala
title Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch
title_short Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch
title_full Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch
title_fullStr Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch
title_full_unstemmed Management of financial conflicts of interests in clinical practice guidelines in Germany: results from the public database GuidelineWatch
title_sort management of financial conflicts of interests in clinical practice guidelines in germany: results from the public database guidelinewatch
publisher BMC
series BMC Medical Ethics
issn 1472-6939
publishDate 2018-06-01
description Abstract Background The reliability of clinical practice guidelines has been disputed because guideline panel members are often burdened with financial conflicts of interest (COI). Current recommendations for COI regulation advise not only detailed declaration but also active management of conflicts. To continuously assess COI declaration and management in German guidelines we established the public database LeitlinienWatch (GuidelineWatch). Methods We analyzed all German guidelines at the highest methodological level (S3) that included recommendations for pharmacological therapy (n = 67) according to five criteria: declaration and assessment of COI, composition of the guideline development group, independence of the coordinators and lead authors, imposed abstentions because of COI and public external review. Each criterion was assessed using predefined outcome categories. Results Most guidelines (76%) contained a detailed declaration of COI. However, none of the guidelines provided full transparency of COI assessment results. The guideline group was composed of a majority of participants with COI in 55% of the guidelines, no guideline was free of participants with COI. Only 9% of guidelines had coordinators and lead authors without any financial COI. Most guidelines (70%) did not provide a rule for abstentions for participants with COI. In 21% of guidelines there was a rule, but abstentions were either not practiced or not documented, whereas in 7% partial abstentions and in 2% complete abstentions were documented. Two thirds of the guideline drafts (67%) were not externally reviewed via a public website. Conclusions COI are usually documented in detail in German guidelines of the highest methodological level. However, considerable improvement is needed regarding active management of COI, including recruitment of independent experts for guideline projects, abstention from voting for participants with COI and external review of the guideline draft. We assume that the publicly available ratings on GuidelineWatch will improve the handling of conflicts of interest in guideline development.
topic Clinical practice guidelines
Conflict of interest
Transparency
Regulation
url http://link.springer.com/article/10.1186/s12910-018-0309-y
work_keys_str_mv AT hendriknapierala managementoffinancialconflictsofinterestsinclinicalpracticeguidelinesingermanyresultsfromthepublicdatabaseguidelinewatch
AT luiseschafer managementoffinancialconflictsofinterestsinclinicalpracticeguidelinesingermanyresultsfromthepublicdatabaseguidelinewatch
AT giselaschott managementoffinancialconflictsofinterestsinclinicalpracticeguidelinesingermanyresultsfromthepublicdatabaseguidelinewatch
AT niklasschurig managementoffinancialconflictsofinterestsinclinicalpracticeguidelinesingermanyresultsfromthepublicdatabaseguidelinewatch
AT thomaslempert managementoffinancialconflictsofinterestsinclinicalpracticeguidelinesingermanyresultsfromthepublicdatabaseguidelinewatch
_version_ 1724463585661288448